Short answer
Perspective Therapeutics, Inc. (CATX) filed an 8-K current report with the SEC on October 1, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Exhibit 99.1 provides Perspective Therapeutics’ corporate presentation for investor reference.
Perspective Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Exhibit 99.1 provides Perspective Therapeutics’ corporate presentation for investor reference
- Filing dated October 1, 2026, signed by CFO Joel Sendek
- Corporate presentation content requires review to assess updated strategy, clinical programs, and financial implications
Item EX-99.1 · Exhibit EX-99.1
- Investor presentation highlights three clinical-stage radiopharmaceutical programs, each targeting distinct cancers with data expected in 2026
- VMT-α-NET Phase 1/2a analysis includes 68 treated patients, supporting potential registration study at the current dose
- VMT01 showed preliminary anti-tumor activity at the 3.0 mCi dose in melanoma
- Pipeline targets a combined $45B+ solid-tumor market across neuroendocrine tumors, melanoma, and advanced solid tumors
- Integrated isotope production and regional manufacturing underpin Perspective’s direct-to-hospital delivery strategy
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Perspective Therapeutics, Inc. 8-K filings
Get the next CATX 8-K as it lands
Follow CATX for push alerts, or ask the research agent what this filing means.